BOSTON, Dec 13 (Reuters) - McKinsey & Co has agreed to pay $650 million to resolve charges over advice it provided Purdue Pharma on how to "turbocharge" sales of its addictive painkiller OxyContin, the U.S. Department of Justice said on Friday.
The consulting firm entered into a five-year deferred prosecution agreement filed in federal court in Abingdon, Virginia, to resolve criminal charges brought as part of the latest corporate prosecution concerning the marketing of addictive painkillers that helped fuel the deadly U.S. opioid epidemic.
A former senior McKinsey partner, Martin Elling, has also agreed to plead guilty to obstructing justice by destroying records concerning McKinsey's work for Purdue. He is set to plead guilty on Jan. 10 and faces up to a year in prison under his plea agreement. His lawyer declined to comment.
